Moreover, the 36-month beta value for NUVB is 1.43. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for NUVB is 134.69M and currently, short sellers hold a 2.37% of that float. On May 08, 2024, NUVB’s average trading volume was 1.43M shares.
NUVB) stock’s latest price update
Nuvation Bio Inc (NYSE: NUVB)’s stock price has increased by 0.31 compared to its previous closing price of 3.18. However, the company has seen a 6.69% increase in its stock price over the last five trading sessions. Business Wire reported 2024-04-24 that NEW YORK–(BUSINESS WIRE)–Nuvation Bio Inc. (NYSE: NUVB), a late-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced that updated data from the Phase 2 TRUST-I clinical study (NCT04395677) evaluating taletrectinib in patients in China with ROS1-positive non-small cell lung cancer (NSCLC) will be reported in an oral presentation at the 2024 American Society of Clinical Oncolo.
NUVB’s Market Performance
Nuvation Bio Inc (NUVB) has seen a 6.69% rise in stock performance for the week, with a -1.24% decline in the past month and a 96.91% surge in the past quarter. The volatility ratio for the week is 5.48%, and the volatility levels for the past 30 days are at 7.03% for NUVB. The simple moving average for the past 20 days is 9.83% for NUVB’s stock, with a 77.64% simple moving average for the past 200 days.
Analysts’ Opinion of NUVB
Many brokerage firms have already submitted their reports for NUVB stocks, with Jefferies repeating the rating for NUVB by listing it as a “Buy.” The predicted price for NUVB in the upcoming period, according to Jefferies is $10 based on the research report published on March 27, 2024 of the current year 2024.
BTIG Research, on the other hand, stated in their research note that they expect to see NUVB reach a price target of $5. The rating they have provided for NUVB stocks is “Buy” according to the report published on March 26th, 2024.
Jefferies gave a rating of “Hold” to NUVB, setting the target price at $2 in the report published on January 06th of the previous year.
NUVB Trading at 17.63% from the 50-Day Moving Average
After a stumble in the market that brought NUVB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -23.31% of loss for the given period.
Volatility was left at 7.03%, however, over the last 30 days, the volatility rate increased by 5.48%, as shares sank -1.24% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +61.11% upper at present.
During the last 5 trading sessions, NUVB rose by +6.69%, which changed the moving average for the period of 200-days by +67.02% in comparison to the 20-day moving average, which settled at $2.90. In addition, Nuvation Bio Inc saw 111.26% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for NUVB
Current profitability levels for the company are sitting at:
- -378.11 for the present operating margin
- 0.29 for the gross margin
The net margin for Nuvation Bio Inc stands at -268.97. The total capital return value is set at -0.16. Equity return is now at value -12.03, with -11.72 for asset returns.
Based on Nuvation Bio Inc (NUVB), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -16.97.
Currently, EBITDA for the company is -99.6 million with net debt to EBITDA at 0.39. When we switch over and look at the enterprise to sales, we see a ratio of 2488.35. The receivables turnover for the company is 0.07for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 44.11.
Conclusion
To wrap up, the performance of Nuvation Bio Inc (NUVB) has been better in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
